A Phase 1 Study of ASP1002 in Participants With Metastatic or Locally Advanced Solid Tumors
This study is testing a new medication called ASP1002, either alone or with standard cancer treatments, in people with advanced solid tumors. ASP1002 attaches to a specific protein on tumor cells to help the body's immune system recognize and attack the cancer. Because this is the first time humans are receiving this drug, the main goals are to check its safety, find the right dose, and see how well patients tolerate it.
Adults with solid tumors that have spread locally or to other parts of the body and cannot be removed by surgery may be eligible. Participants must have previously tried standard treatments or chosen not to take them, and they must meet specific health requirements regarding their heart, brain, and immune system.
Participants will receive the study treatment through an intravenous infusion every few weeks in cycles lasting up to two years or until the cancer worsens. You will visit the clinic regularly for health checks, routine scans to monitor the tumor, and safety reviews. Follow-up health checks will continue for up to one year after your last dose.
This study is currently recruiting participants at multiple locations, including sites in New Haven and Plainville, Connecticut, and Gainesville, Florida.
- 1Testing a new drug called ASP1002 to see if it helps the immune system fight advanced cancer.
- 2The study looks at safety and finds the best dose, both on its own and combined with standard treatments.
- 3Participants receive treatment through regular infusions and have frequent health monitoring and scans.
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.